|Day Low/High||12.01 / 12.71|
|52 Wk Low/High||6.07 / 13.76|
This pharma company is still making lots of money and its stock is too cheap to pass up.
Teva Pharmaceuticals plunged on Friday amid weaker-than-expected 2017 guidance.
Not much action in the markets since our last update with the major indices continuing to grind slightly higher as we try to close out a solid first trading week of 2017 on a high note. Think Teva Pharmaceuticals getting oversold today on slightly r...
The biggest annual event for biotech and pharma investors starts Monday with the kickoff of the J.P. Morgan Healthcare Conference in San Francisco.
Drug giants with money to spend and a friendlier regulatory environment should spur deals.
We touched briefly on housing in our first post this morning. There are still some cheap home-building stocks if the housing market continues to improve, which I expect as I believe economic growth will pick up in 2017. I have done well with this se...
Here are stocks with solid fundamentals at some of the best absolute entry points in years.
Wait for a bounce and then a retest before stepping up to buy.
'Milestone payments' could boost deal's $125 million announced price.
And we are off. The market has opened opens slightly lower across the board. We're seeing some profit taking early on in stocks and sectors that have done extremely well since the election. United Rentals , after massive run over the past week, is d...
It is good to be standing in for Doug Kass this Wednesday. We saw somewhat of a snapback rally yesterday in some of the sectors that have underperformed since the unexpected election results last week. Technology was up nearly 1.5% within a decent d...
In these market crosscurrents, it's tough to go with the flow.
Thursday felt a lot like capitulation in this space. I was buying.
I have been warning about weakening breadth and narrow leadership for weeks and months. What have we gotten? Eight straight days (in a row) down for the first time since 2008. But, with stocks suffering from election uncertainties and given the ...
News announcements from these companies are supportive of continued strength.
News announcements from these companies is supportive of continued strength.
Allergan is a winner but it is a bad time to own drug stocks, says Jim Cramer.
The likely continuation of a split government should help the sector recover from its recent beat-down.
Shares of Regeneron Pharmaceuticals were lower Monday after The Food and Drug Administration put a drug study on hold.
Problems have hit some favorite names, but opportunities are becoming apparent.
Attacking Big Pharma price gougers may be all that unifies the candidates ahead of tonight's debate.
There are no bullish divergences of consequence to suggest that the stock might be poised to rally.